Skip to main content
. Author manuscript; available in PMC: 2011 Apr 11.
Published in final edited form as: Antivir Ther. 2007;12(4):543–551.

Figure 1.

Figure 1

Figure 1

Figure 1A: Crude incidence rates of any first severe opportunistic disease stratified by CD4 count and HAART use. Error bars represent the upper bound of the 95% confidence interval.

Figure 1B: Crude incidence rates of first severe opportunistic disease stratified by CD4 count, HAART use, and response to cotrimoxazole. Error bars represent the upper bound of the 95% confidence interval.